Planning for Implementation of Decentralized Clinical Trials in APAC: A Global Overview

About this Webinar

Focus on decentralized clinical trials (DCTs) has taken a massive leap over the course of the pandemic. COVID-19 forced an accelerated use of telemedicine, home health options and digital applications to keep studies running. Emerging from COVID-19, the use of decentralized solutions continues to rise worldwide. Although somewhat slower to adopt, the Asia-Pacific region has seen a dramatic shift in elements critical to implementation of decentralized solutions, including emerging clarity in regulatory guidance and greater acceptance of home health services, which will serve as important drivers of accelerated future use of DCT.

As APAC developers continue to explore opportunities to incorporate DCT into their clinical strategies, understanding what is working well in other markets – whether it be with the intent of leveraging to bring their asset into those markets or with an eye toward adapting these best practices to the unique APAC landscape – is key to success.

Key Takeaways:

In this webinar, attendees will:

Learn implementation tactics and benefits of DCT in the US and Europe
Review case studies illustrating best practices for DCT implementation – and how these can be applied to APAC trials
Understand critical regulatory, site-specific and cultural implications to consider when applying DCT in APAC

Audience:

APAC-based biopharmaceutical professionals engaged in Clinical Operations functions.

Speakers:

Francesca Scaramozzino

Senior Project Director

Syneos Health

[email protected]

Dr. Scaramozzino brings over 15 years’ experience in clinical research to her role at Syneos Health. Her expertise spans project management and clinical management of all phases of global clinical studies in multiple therapeutic areas, including extensive experience in Asia emerging markets and fast-growing markets such as China and Korea, especially in the Real World Evidence arena.

Prior to joining Syneos Health, Dr. Scaramozzino served as Head of Real World Evidence at Vista Health Pte. Ltd., and as Head of Data Generation, Real World Evidence, APAC at IQVIA.

She received her Ph.D. in Biochemistry and Molecular Biology at Università degli Studi di Pavia in Milan.

Russell Griffith

DCT Manager

Syneos Health

[email protected]

Russell has more than 12 years of experience in the CRO environment. As a global project manager he has managed large, global, phase II/III studies in a variety of areas, primarily focused on rare disease respiratory studies. As a project manager he implemented decentralized solutions and saw the need for the industry to continue to grow in decentralized offerings to best meet patient and client needs. Russell now serves as a DCT Manager working to guide project team within Syneos to help studies effectively apply decentralized solutions that decrease the patient and site burden and enhance clinical trial outcomes.

Kevin Wightman

Senior Director, Corporate and Business Development

Illingworth Research Group

[email protected]

With more than 25 years’ experience in leading Pharma, CRO, site and patient centric solutions providers across Asia Pacific, US and Europe, Kevin is passionate about improving the way clinical trials are delivered to better meet patients’ needs. With industry association and not-for-profit Board Director experience, Kevin brings unique perspectives, stakeholder networks and insights from both industry and site angles. In his role as Senior Director Corporate and Business Development, leading Illingworth Research Group’s expansion in the Asia Pacific region, Kevin continues to follow his passion as a “patient pioneer,” making clinical trials more accessible and less burdensome for patients and their families and carers. Kevin originally graduated in Pharmacology from Nottingham University in the UK and has worked in Australia for over 20 years.